A comparative, double-blind, randomised trial of a new second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism

Thrombosis and Haemostasis

Volumn 83, Issue 4, 2000, Pages 523-529

  Kakkar, V V ^a   Howes, J ^a   Sharma, V ^a   Kadziola, Z ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Heparin; Prevention of venous thromboembolism

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOMA; HIP ARTHROPLASTY; HIP DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0034106458     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613856     Document Type: Article

References (31)

1. Leizorovicz A, Haugh MC, Chapuis F, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20.
2. Kakkar VV. International multicentre trial: Prevention of postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51.
3. Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Brit Med J 1982; 284: 375-9.
4. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and anti-thrombotic properties of low molecular weight heparins and heparin in rabbits. Blood 1982; 59 (6): 1239-45.
5. Hemker HC, Beguin S. Mode of action of heparin and related drugs. Semin.Thromb Haemost 1991; 17 (suppl 1): 29-34.
6. Human Blood Coagulation, Haemostasis and Thrombosis. Ed. Rosemary Briggs. Pub. Blackwell Scientific Pub. Oxford 1975.
7. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10 (3): 399-410.
8. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50 (6): 803-13.
9. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group. Am J Surg 1970; 120: 527-30.
10. Kakkar VV, Cohen AT, Edmondson RA, et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
11. Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group. Thromb Res 1992; 65 (4-5): 641-50.
12. Thomas DP, Morton RE, Gray E, Barrowcliffe TW. The relative anti-thrombotic effectiveness of heparin, a low molecular weight heparin and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61 (2): 204-7.
13. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-Xa level and clinical outcome in patients receiving enoxaparine (LMWH) to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62 (3): 940-4.
14. Dahl OE, Aspelin T, Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coag Fibrin 1995; 6: 709-17.
15. Dahl OE, Aspelin T, Arnesen H, Seljeflot I, Kierrulf P, Ruyter R, Lyberg T. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
16. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomised trials in general, orthopaedic and urological surgery. New Eng J Med 1988; 318: 1162-73.
17. Hull RD, Brant TF, Pineo GE, et al. Pre-operative versus postoperative initiation of low molecular weight heparin prophylaxis against thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159 (2): 137-41.
18. Lumpkin MM, FDA alert. FDA public health advisory. Anesthesiology 1998; 88 (2): 27A-8A.
19. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anaesthetic management. Anesth Analg 1997; 85: 874-85.
20. Dahlagren N, Tombrandt K. Neurological complications after anaesthesia: a follow up of 18,000 spinal and epidural anaesthetics performed over three years. Acta Anaesthesiol Scand 1995; 39: 872-80.
21. Bergqvist D, Linblad B, Matzsch T. Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia - is there a risk? Acta Anesthesiol Scand 1992; 36: 605-9.
22. Lund PC. Peridural anaesthesia. Springfield Illinois. Charles C. Thomas 1966.
23. Tryba M. Epidural regional anaesthesia and low molecular weight heparin. Pro. Anesthesiol. Intensivmed. Notfallmed Schmerzther 1993; 28: 179-81.
24. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79: 1165-77.
25. Trowlidge A, Boese LK, Woodruff B, Brindley HH, Lowry WE, Spiro TE. Incidence of post-hospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. Clin Orthop 1994; 299: 203-8.
26. Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. BMJ 1977; 2: 223-5.
27. Dahl OE, Molnar I, Vinje A, Ro JS, et al. Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement. Thromb Res 1988; 50; 875-84.
28. Dahl OE, Anderson G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery. Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997; 77 (1): 26-61.
29. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro H.P. et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) alter total hip arthroplasty - the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89 (6): 281-7.
30. Bergqvist D, Benoni G, Bjorgell O, Fredin et al. Low molecular weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Eng J Med 1996; 335: 696-700.
31. Planes A, Vochello M, Darmon JY et al. Risk of deep vein thrombosis after hospital discharge in patients having undergone total hip replacement: double-blinded randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.